rs41312024

Variant summary

Our verdict is Benign. The variant received -19 ACMG points: 0P and 19B. BP4_ModerateBP6_Very_StrongBP7BS1BS2

The NM_001365999.1(SZT2):​c.348C>A​(p.Ile116Ile) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0141 in 1,613,574 control chromosomes in the GnomAD database, including 204 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.012 ( 21 hom., cov: 32)
Exomes 𝑓: 0.014 ( 183 hom. )

Consequence

SZT2
NM_001365999.1 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:6

Conservation

PhyloP100: 1.05

Publications

7 publications found
Variant links:
Genes affected
SZT2 (HGNC:29040): (SZT2 subunit of KICSTOR complex) The protein encoded by this gene is expressed in the brain, predominantly in the parietal and frontal cortex as well as in dorsal root ganglia. It is localized to the peroxisome, and is implicated in resistance to oxidative stress. It likely functions by increasing superoxide dismutase (SOD) activity, but itself has no direct SOD activity. Studies in mice show that this gene confers low seizure threshold, and may also enhance epileptogenesis. [provided by RefSeq, Jun 2011]
SZT2 Gene-Disease associations (from GenCC):
  • developmental and epileptic encephalopathy, 18
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), G2P, Illumina
  • genetic developmental and epileptic encephalopathy
    Inheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
  • undetermined early-onset epileptic encephalopathy
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -19 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.28).
BP6
Variant 1-43404400-C-A is Benign according to our data. Variant chr1-43404400-C-A is described in ClinVar as Benign. ClinVar VariationId is 416961.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=1.05 with no splicing effect.
BS1
Variant frequency is greater than expected in population nfe. GnomAd4 allele frequency = 0.0119 (1817/152276) while in subpopulation NFE AF = 0.0181 (1229/68026). AF 95% confidence interval is 0.0172. There are 21 homozygotes in GnomAd4. There are 888 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check.
BS2
High Homozygotes in GnomAd4 at 21 AR,AD gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
SZT2NM_001365999.1 linkc.348C>A p.Ile116Ile synonymous_variant Exon 4 of 72 ENST00000634258.3 NP_001352928.1
SZT2NM_015284.4 linkc.348C>A p.Ile116Ile synonymous_variant Exon 4 of 71 NP_056099.3

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
SZT2ENST00000634258.3 linkc.348C>A p.Ile116Ile synonymous_variant Exon 4 of 72 5 NM_001365999.1 ENSP00000489255.1

Frequencies

GnomAD3 genomes
AF:
0.0119
AC:
1818
AN:
152158
Hom.:
21
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00391
Gnomad AMI
AF:
0.0625
Gnomad AMR
AF:
0.0109
Gnomad ASJ
AF:
0.00864
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000829
Gnomad FIN
AF:
0.0131
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0181
Gnomad OTH
AF:
0.0148
GnomAD2 exomes
AF:
0.0114
AC:
2868
AN:
250858
AF XY:
0.0113
show subpopulations
Gnomad AFR exome
AF:
0.00295
Gnomad AMR exome
AF:
0.00797
Gnomad ASJ exome
AF:
0.00757
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.0133
Gnomad NFE exome
AF:
0.0182
Gnomad OTH exome
AF:
0.0133
GnomAD4 exome
AF:
0.0144
AC:
21003
AN:
1461298
Hom.:
183
Cov.:
30
AF XY:
0.0141
AC XY:
10229
AN XY:
726884
show subpopulations
African (AFR)
AF:
0.00251
AC:
84
AN:
33474
American (AMR)
AF:
0.00850
AC:
380
AN:
44698
Ashkenazi Jewish (ASJ)
AF:
0.00877
AC:
229
AN:
26124
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39688
South Asian (SAS)
AF:
0.00121
AC:
104
AN:
86126
European-Finnish (FIN)
AF:
0.0131
AC:
699
AN:
53358
Middle Eastern (MID)
AF:
0.00438
AC:
25
AN:
5708
European-Non Finnish (NFE)
AF:
0.0169
AC:
18778
AN:
1111748
Other (OTH)
AF:
0.0117
AC:
704
AN:
60374
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.469
Heterozygous variant carriers
0
1002
2004
3006
4008
5010
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
688
1376
2064
2752
3440
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0119
AC:
1817
AN:
152276
Hom.:
21
Cov.:
32
AF XY:
0.0119
AC XY:
888
AN XY:
74448
show subpopulations
African (AFR)
AF:
0.00390
AC:
162
AN:
41550
American (AMR)
AF:
0.0109
AC:
166
AN:
15296
Ashkenazi Jewish (ASJ)
AF:
0.00864
AC:
30
AN:
3472
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5172
South Asian (SAS)
AF:
0.000622
AC:
3
AN:
4822
European-Finnish (FIN)
AF:
0.0131
AC:
139
AN:
10616
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.0181
AC:
1229
AN:
68026
Other (OTH)
AF:
0.0147
AC:
31
AN:
2116
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.497
Heterozygous variant carriers
0
94
188
281
375
469
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
24
48
72
96
120
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0112
Hom.:
4
Bravo
AF:
0.0120
Asia WGS
AF:
0.000866
AC:
3
AN:
3478
EpiCase
AF:
0.0158
EpiControl
AF:
0.0144

ClinVar

Significance: Benign
Submissions summary: Benign:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:3
Feb 02, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Sep 18, 2019
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Developmental and epileptic encephalopathy, 18 Benign:1
Apr 11, 2023
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Benign:1
Dec 06, 2024
Athena Diagnostics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Inborn genetic diseases Benign:1
Apr 26, 2016
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.28
CADD
Benign
12
DANN
Benign
0.73
PhyloP100
1.1
Mutation Taster
=100/0
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.050
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs41312024; hg19: chr1-43870071; API